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Pulmonary Disease 
Caused by  
Mycobacterium 
marseillense, Italy
To the Editor: Mycobacterium 
marseillense was recently described as 
a new species belonging to the Myco-
bacterium avium complex (MAC) (1). 
We describe a case of pulmonary dis-
ease caused by M. marseillense in an 
immunocompetent patient. All strains 
isolated from the patient were prelimi-
narily identified as M. intracellulare; 
however, a retrospective molecular 
analysis corrected the identification to 
M. marseillense.
In December 2005, a 65-year-
old man was admitted to the Univer-
sity Hospital, Modena, Italy, with a 
2-week history of fever, cough, and 
hemoptysis. Physical examination 
detected diffuse rales, and chest ra-
diographs showed a diffuse nodular 
opacity and bronchial thickening, 
confirmed by high-resolution com-
puted tomography (CT) of the chest 
(Figure, panel A). The patient had ex-
perienced several previous episodes 
of hemoptysis and persistent produc-
tive cough since 1998, and tubular 
bronchiectasis had been detected on 
previous high-resolution CT images. 
The patient had a history of thalas-
semia minor, was HIV negative, 
and was formerly a mild smoker (10 
cigarettes/day for 4 years during his 
youth). He had no chronic disorders 
and no history of immunosuppres-
sive-drug or alcohol use.
Bacterial and fungal cultures and 
a smear for acid-fast bacilli performed 
on a bronchoalveolar lavage (BAL) 
sample were all negative. A nontu-
berculous mycobacterium strain was 
isolated by culture and preliminar-
ily identified as M. intracellulare by 
using the GenoType Mycobacterium 
CM/AS Kit (Hain Lifesciences, Ne-
hren, Germany). At that time, a drug 
susceptibility test for isoniazid, ri-
fampin, streptomycin, and ethambutol 
was improperly performed (i.e., was 
not applicable for MAC) by using 
the agar proportion method; sensitiv-
ity information for macrolides was 
unavailable. The strain was resistant 
to ethambutol and susceptible to the 
other drugs. The physician prescribed 
rifampin, isoniazid, and amikacin. 
After remission of fever and hemop-
tysis and improvement of chronic 
cough, the patient was discharged 
from the hospital.
In March 2006, he was readmit-
ted to the hospital for worsening of 
his condition and onset of side effects 
associated with rifampin and isonia-
zid use. The treatment was discon-
tinued and replaced by levofloxacin, 
terizidone, and azithromycin, which 
resulted in remission of symptoms. 
This therapy was continued after hos-
pital discharge.
In 2007, the patient was twice ad-
mitted for follow-up and microbiolog-
ical testing to determine bacteriologic 
status. All 3 separate sputum samples 
were negative for mycobacteria, other 
bacteria, and fungi. However, BAL 
sample culture results were positive 
for the same mycobacterium despite 
continued therapy with levofloxacin, 
terizidone, and azithromycin.
During 2008, as an investigation 
of the possibility of persistent excre-
tion of organisms, additional samples 
were collected 5 times. The sputum 
cultures were intermittently positive, 
while the BAL sample cultures were 
persistently positive.
In May 2009, after the patient 
had been persistently stable and had 
negative culture results for 14 months, 
the antimicrobial drug therapy was 
stopped. In December 2010, the pa-
tient’s only symptom was persistent 
productive cough; however, the spu-
tum culture was again positive, and 
high-resolution CT revealed a wors-
ening condition of his lungs (Figure, 
panel B). A new antimycobacterial 
drug regimen of ethambutol, rifampin, 
and azithromycin was started, in 
accordance with the international 
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guidelines of the American Thoracic 
Society and the Infectious Diseases 
Society of America (2).
After the patient had received 6 
months of therapy, the sputum culture 
result was again negative. The acid-
fast bacilli smear and culture results 
remained negative until November 
2012. The latest treatment resulted in 
recovery from symptoms and a more 
stable condition. However, cough and 
sputum production, although attenu-
ated, persisted despite treatment and 
negative microbiological test results. 
High-resolution CT images (Figure, 
panel C) indicated overall progression 
of pulmonary involvement from the 
time of first admission.
In February 2011, on the basis of 
the known cross-reactivity of the M. 
intracellulare probe with most MAC 
species when the GenoType Myco-
bacterium CM/AS assay is used (3), 
we determined the sequences of a 
portion of the rpoB gene and inter-
nal transcribed spacer–1 region in 2 
strains isolated from sputum in March 
2006 and June 2010. All sequences 
overlapped with M. marseillense type 
strain sequences in GenBank, show-
ing an identity of 100% in internal 
transcribed spacer–1 with EU266631 
and 99.8% (1 mismatch) in rpoB 
with EF584434. 
We therefore show the association 
of M. marseillense infection with pul-
monary disease in an immunocompetent 
patient, helping define the clinical fea-
tures and natural history of pulmonary 
disease caused by M. marseillense. We 
cannot assert whether the clinical course 
is associated with the intrinsic charac-
teristics of M. marseillense infection or 
with the therapeutic regimen, possibly 
influenced by numerous adverse effects 
that may have compromised its effec-
tiveness. More careful management in 
accordance with the American Thoracic 
Society and the Infectious Diseases So-
ciety of America guidelines for manage-
ment of nontuberculous mycobacterial 
diseases could have achieved a more 
effective course of treatment. More case 
reports of pulmonary disease caused by 
M. marseillense are needed to support 
our observations and to provide more 
insight into its clinical picture.
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Figure.	High-resolution	 computed	 tomographic	 chest	 images	of	 a	man	with	prolonged	pulmonary	disease	 caused	by	Mycobacterium 
marseillense, Italy.	A)	October	6,	2005.	Bilateral	bronchiectasis,	mainly	in	the	middle	lobe	and	lingula,	associated	with	multiple	nodules	
and	middle	 lobe	consolidation.	B)	June	7,	2010.	 Increased	micronodular	opacities,	mainly	 in	 the	 right	middle	and	 lower	 lobes,	and	a	
worsening	of	the	bronchiectasis.	C)	August	3,	2013.	Persistence	of	nodular	component,	cavitation,	and	wider	bronchiectasis	with	bronchial	
wall	thickening.
